Nivolumab + ipilimumab (RCC)
Checked 2026-09-09
Untreated advanced clear-cell RCC, IMDC intermediate or poor risk
One cycle
every 21 days × 4 · about 12 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Nivolumab Monoclonal antibody (anti-PD-1) | 3 mg/kg | IV | D1 | |
Ipilimumab Monoclonal antibody (anti-CTLA-4) | 1 mg/kg | IV | D1 |
Cycles
4 combination, then nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks
21-day cycle
Emetogenicity
Minimal (<10%)
G-CSF
Not routine
Used in
Trials
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Everolimus
Advanced progressive NET (RADIANT-3, RADIANT-4); RCC and HR-positive breast cancer after prior therapy
every 28 days
Pembrolizumab + axitinib
Untreated advanced clear-cell RCC, any IMDC risk
every 21 days
Sunitinib 4/2
Advanced clear-cell RCC favourable risk or when immunotherapy is contraindicated; imatinib-resistant GIST; pancreatic NET
every 42 days